{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:35:17Z","timestamp":1774895717551,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne Muscular Dystrophy (DMD) is a progressive and fatal muscle-wasting disease with no known cure. We\u00a0previously reported the preliminary safety and efficacy up to six months after the administration of DT-DEC01, a\u00a0novel Dystrophin Expressing Chimeric (DEC) cell therapy created by fusion of myoblasts of DMD patient and the normal donor. In this 12-month follow-up study, we report on the safety and functional outcomes of three DMD patients after the systemic intraosseous administration of DT-DEC01. The safety of DT-DEC01 was confirmed by the absence of Adverse Events (AE) and Severe Adverse Events (SAE) up to 21\u00a0months after intraosseous DT-DEC01 administration. The lack of presence of anti-HLA antibodies and Donors Specific Antibodies (DSA) further confirmed DT-DEC01 therapy safety. Functional assessments in ambulatory patients revealed improvements in 6-Minute Walk Test (6MWT) and timed functions of North Star Ambulatory Assessment (NSAA). Additionally, improvements in PUL2.0 test and grip strength correlated with increased Motor Unit Potentials (MUP) duration recorded by Electromyography (EMG) in both ambulatory and non-ambulatory patients. DT-DEC01 systemic effect was confirmed by improved cardiac and pulmonary parameters and daily activity recordings. This follow-up study confirmed the safety and preliminary efficacy of DT-DEC01 therapy in DMD-affected patients up to 12\u00a0months after intraosseous administration. DT-DEC01 introduces a novel concept of personalized myoblast-based cellular therapy that is irrespective of the mutation type, does not require immunosuppression or the use of viral vectors, and carries no risk of off target mutations. This\u00a0establishes DT-DEC01 as a promising and universally effective treatment option for all DMD patients.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s12015-023-10620-3","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:52Z","timestamp":1694699452000},"page":"2724-2740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up\u00a0Study After Systemic Intraosseous Administration"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6122","authenticated-orcid":false,"given":"Maria","family":"Siemionow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Biega\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Niezgoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Czarnota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Siemionow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ziemiecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria H.","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Bo\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlke","family":"Heydemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"10620_CR1","doi-asserted-by":"publisher","unstructured":"Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., \u2026 Constantin, C. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 9(1), 77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"10620_CR2","doi-asserted-by":"publisher","unstructured":"Porcher, R., Desguerre, I., Amthor, H., Chabrol, B., Audic, F., Rivier, F., \u2026 Wahbi, K. (2021). Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy\u2014analysis of registry data. European Heart Journal, 42(20), 1976\u20131984. https:\/\/doi.org\/10.1093\/eurheartj\/ehab054","DOI":"10.1093\/eurheartj\/ehab054"},{"issue":"1","key":"10620_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo, S. M., Salhany, R. M., Deighton, A., Harwood, M., Mah, J., & Gooch, K. L. (2021). The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: A systematic literature review. Orphanet Journal of Rare Diseases, 16(1), 237. https:\/\/doi.org\/10.1186\/s13023-021-01862-w","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10620_CR4","doi-asserted-by":"publisher","unstructured":"Van Ruiten, H. J. A., Marini Bettolo, C., Cheetham, T., Eagle, M., Lochmuller, H., Straub, V., \u2026 Guglieri, M. (2016). Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. European Journal of Paediatric Neurology, 20(6), 904\u2013909. https:\/\/doi.org\/10.1016\/j.ejpn.2016.07.020","DOI":"10.1016\/j.ejpn.2016.07.020"},{"issue":"2","key":"10620_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","volume":"37","author":"L Wahlgren","year":"2022","unstructured":"Wahlgren, L., Kroksmark, A.-K., Tulinius, M., & Sofou, K. (2022). One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. European Journal of Epidemiology, 37(2), 147\u2013156. https:\/\/doi.org\/10.1007\/s10654-021-00819-4","journal-title":"European Journal of Epidemiology"},{"issue":"1","key":"10620_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J.B., & Kunkel, L. M. (2015). The pathogenesis and therapy of muscular dystrophies. Annual Review of Genomics and Human Genetics, 16(1), 281\u2013308. https:\/\/doi.org\/10.1146\/annurev-genom-090314-025003","journal-title":"Annual Review of Genomics and Human Genetics"},{"key":"10620_CR7","doi-asserted-by":"publisher","unstructured":"Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., \u2026 Muntoni, F. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378(9791), 595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(11)60756-3","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"10620_CR8","doi-asserted-by":"publisher","unstructured":"Aartsma-Rus, A., Straub, V., Hemmings, R., Haas, M., Schlosser-Weber, G., Stoyanova-Beninska, V., \u2026 Balabanov, P. (2017). Development of exon skipping therapies for Duchenne muscular dystrophy: A critical review and a perspective on the outstanding issues. Nucleic Acid Therapeutics, 27(5), 251\u2013259. https:\/\/doi.org\/10.1089\/nat.2017.0682","DOI":"10.1089\/nat.2017.0682"},{"issue":"1","key":"10620_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi, Y., Murakami, T., Kimura, E., Komaki, H., & Watanabe, N. (2018). Exon skipping for Duchenne muscular dystrophy: A systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 13(1), 93. https:\/\/doi.org\/10.1186\/s13023-018-0834-2","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10620_CR10","doi-asserted-by":"publisher","unstructured":"Clemens, P. R., Rao, V. K., Connolly, A. M., Harper, A. D., Mah, J. K., Smith, E. C., \u2026 Hoffman, E. P. (2020). Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 Skipping. JAMA Neurology, 77(8), 1\u201310. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"10620_CR11","doi-asserted-by":"publisher","unstructured":"Servais, L., Mercuri, E., Straub, V., Guglieri, M., Seferian, A. M., Scoto, M., \u2026 SKIP-NMD Study Group. (2022). Long-term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: A first-in-human, multicenter, two-part, open-label, Phase 1\/2 trial. Nucleic Acid Therapeutics, 32(1), 29\u201339. https:\/\/doi.org\/10.1089\/nat.2021.0043","DOI":"10.1089\/nat.2021.0043"},{"issue":"s2","key":"10620_CR12","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan, N., & Dickson, G. (2021). Gene therapy for Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 8(s2), S303\u2013S316. https:\/\/doi.org\/10.3233\/JND-210678","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"s2","key":"10620_CR13","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JND-210683","volume":"8","author":"J Morgan","year":"2021","unstructured":"Morgan, J., & Muntoni, F. (2021). Changes in Myonuclear number during postnatal growth \u2013 implications for AAV gene therapy for muscular dystrophy. Journal of Neuromuscular Diseases, 8(s2), S317\u2013S324. https:\/\/doi.org\/10.3233\/JND-210683","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10620_CR14","doi-asserted-by":"publisher","unstructured":"Clemens, P. R., Rao, V. K., Connolly, A. M., Harper, A. D., Mah, J. K., McDonald, C. M., \u2026 Hoffman, E. P. (2022). Long-term functional efficacy and safety of Viltolarsen in patients with Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 9(4), 493\u2013501. https:\/\/doi.org\/10.3233\/JND-220811","DOI":"10.3233\/JND-220811"},{"key":"10620_CR15","doi-asserted-by":"publisher","unstructured":"Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., \u2026 Rodino-Klapac, L. R. (2020). Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne muscular dystrophy: A nonrandomized controlled trial. JAMA Neurology, 77(9), 1122\u20131131. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"10620_CR16","unstructured":"Solid Biosciences Inc. (2023). A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I\/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy (Clinical trial registration No. NCT03368742). clinicaltrials.gov. Retrieved from \nhttps:\/\/clinicaltrials.gov\/study\/NCT03368742.\u00a0Accessed 09 Aug 2023."},{"key":"10620_CR17","doi-asserted-by":"publisher","unstructured":"Birch, S. M., Lawlor, M. W., Conlon, T. J., Guo, L.-J., Crudele, J. M., Hawkins, E. C., \u2026 Kornegay, Joe. N. (2023). Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Science Translational Medicine, 15(677), eabo1815. https:\/\/doi.org\/10.1126\/scitranslmed.abo1815","DOI":"10.1126\/scitranslmed.abo1815"},{"issue":"9","key":"10620_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nm0997-970","volume":"3","author":"E Gussoni","year":"1997","unstructured":"Gussoni, E., Blau, H. M., & Kunkel, L. M. (1997). The fate of individual myoblasts after transplantation into muscles of DMD patients. Nature Medicine, 3(9), 970\u2013977. https:\/\/doi.org\/10.1038\/nm0997-970","journal-title":"Nature Medicine"},{"issue":"9","key":"10620_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1517\/14712598.2015.1057564","volume":"15","author":"D Skuk","year":"2015","unstructured":"Skuk, D., & Tremblay, J. P. (2015). Cell therapy in muscular dystrophies: Many promises in mice and dogs, few facts in patients. Expert Opinion on Biological Therapy, 15(9), 1307\u20131319. https:\/\/doi.org\/10.1517\/14712598.2015.1057564","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10620_CR20","doi-asserted-by":"publisher","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","volume":"323","author":"C Sun","year":"2020","unstructured":"Sun, C., Serra, C., Lee, G., & Wagner, K. R. (2020). Stem cell-based therapies for Duchenne muscular dystrophy. Experimental Neurology, 323, 113086. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113086","journal-title":"Experimental Neurology"},{"issue":"20","key":"10620_CR21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/scd.2016.0136","volume":"25","author":"LA Muir","year":"2016","unstructured":"Muir, L. A., Murry, C. E., & Chamberlain, J. S. (2016). Prosurvival factors improve functional engraftment of Myogenically converted dermal cells into dystrophic skeletal muscle. Stem Cells and Development, 25(20), 1559\u20131569. https:\/\/doi.org\/10.1089\/scd.2016.0136","journal-title":"Stem Cells and Development"},{"issue":"7","key":"10620_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1399-3046.2010.01377.x","volume":"14","author":"B Palmieri","year":"2010","unstructured":"Palmieri, B., Tremblay, J. P., & Daniele, L. (2010). Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy: Myoblast to treat Duchenne. Pediatric Transplantation, 14(7), 813\u2013819. https:\/\/doi.org\/10.1111\/j.1399-3046.2010.01377.x","journal-title":"Pediatric Transplantation"},{"issue":"10","key":"10620_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","volume":"28","author":"F Barth\u00e9l\u00e9my","year":"2018","unstructured":"Barth\u00e9l\u00e9my, F., & Wein, N. (2018). Personalized gene and cell therapy for Duchenne muscular dystrophy. Neuromuscular Disorders, 28(10), 803\u2013824. https:\/\/doi.org\/10.1016\/j.nmd.2018.06.009","journal-title":"Neuromuscular Disorders"},{"issue":"11","key":"10620_CR24","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1172\/JCI142031","volume":"130","author":"S Biressi","year":"2020","unstructured":"Biressi, S., Filareto, A., & Rando, T. A. (2020). Stem cell therapy for muscular dystrophies. Journal of Clinical Investigation, 130(11), 5652\u20135664. https:\/\/doi.org\/10.1172\/JCI142031","journal-title":"Journal of Clinical Investigation"},{"key":"10620_CR25","doi-asserted-by":"publisher","unstructured":"Meregalli, M., Farini, A., Belicchi, M., Parolini, D., Cassinelli, L., Razini, P., \u2026 Torrente, Y. (2013). Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS Journal, 280(17), 4251\u20134262. https:\/\/doi.org\/10.1111\/febs.12083","DOI":"10.1111\/febs.12083"},{"key":"10620_CR26","doi-asserted-by":"publisher","unstructured":"Sitzia, C., Farini, A., Jardim, L., Razini, P., Belicchi, M., Cassinelli, L., \u2026 Torrente, Y. (2016). Adaptive immune response impairs the efficacy of autologous transplantation of engineered stem cells in dystrophic dogs. Molecular Therapy, 24(11), 1949\u20131964. https:\/\/doi.org\/10.1038\/mt.2016.163","DOI":"10.1038\/mt.2016.163"},{"issue":"6273","key":"10620_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/345350a0","volume":"345","author":"SM Hughes","year":"1990","unstructured":"Hughes, S. M., & Blau, H. M. (1990). Migration of myoblasts across basal lamina during skeletal muscle development. Nature, 345(6273), 350\u2013353. https:\/\/doi.org\/10.1038\/345350a0","journal-title":"Nature"},{"issue":"2","key":"10620_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2018). Creation of dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 14(2), 189\u2013199. https:\/\/doi.org\/10.1007\/s12015-017-9792-7","journal-title":"Stem Cell Reviews and Reports"},{"issue":"3","key":"10620_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia, J., Marchese, E., Siemionow, K., & Szilagyi, E. (2018). Dystrophin Expressing Chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 14(3), 370\u2013384. https:\/\/doi.org\/10.1007\/s12015-018-9807-z","journal-title":"Stem Cell Reviews and Reports"},{"issue":"6","key":"10620_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","volume":"15","author":"M Siemionow","year":"2019","unstructured":"Siemionow, M., Malik, M., Langa, P., Cwykiel, J., Brodowska, S., & Heydemann, A. (2019). Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx mouse model of Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 15(6), 827\u2013841. https:\/\/doi.org\/10.1007\/s12015-019-09916-0","journal-title":"Stem Cell Reviews and Reports"},{"issue":"10","key":"10620_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/sctm.21-0054","volume":"10","author":"M Siemionow","year":"2021","unstructured":"Siemionow, M., Langa, P., Harasymczuk, M., Cwykiel, J., Sielewicz, M., Smieszek, J., & Heydemann, A. (2021). Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle\u2019s function in Duchenne muscular dystrophy. STEM CELLS Translational Medicine, 10(10), 1406\u20131418. https:\/\/doi.org\/10.1002\/sctm.21-0054","journal-title":"STEM CELLS Translational Medicine"},{"key":"10620_CR32","doi-asserted-by":"publisher","DOI":"10.5114\/aic.2021.110990","author":"M Malik","year":"2021","unstructured":"Malik, M., Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2021). Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy. Advances in Interventional Cardiology. https:\/\/doi.org\/10.5114\/aic.2021.110990","journal-title":"Advances in Interventional Cardiology"},{"key":"10620_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10384-2","author":"M Siemionow","year":"2022","unstructured":"Siemionow, M., Langa, P., Brodowska, S., Kozlowska, K., Zalants, K., Budzynska, K., & Heydemann, A. (2022). Long-term protective effect of human Dystrophin Expressing Chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-022-10384-2","journal-title":"Stem Cell Reviews and Reports"},{"issue":"1","key":"10620_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00005-022-00656-7","volume":"70","author":"M Siemionow","year":"2022","unstructured":"Siemionow, M., Brodowska, S., Langa, P., Zalants, K., Kozlowska, K., Grau-Kazmierczak, W., & Heydemann, A. (2022). Long-Term biodistribution and safety of human dystrophin expressing chimeric cell therapy after systemic-intraosseous administration to Duchenne muscular dystrophy model. Archivum Immunologiae et Therapiae Experimentalis, 70(1), 20. https:\/\/doi.org\/10.1007\/s00005-022-00656-7","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10620_CR35","doi-asserted-by":"publisher","unstructured":"Heydemann, A., Bieganski, G., Wachowiak, J., Czarnota, J., Niezgoda, A., Siemionow, K., \u2026 Siemionow, M. (2023). Dystrophin Expressing Chimeric (DEC) cell therapy for Duchenne muscular dystrophy: A first-in-human study with minimum 6 months follow-up. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-023-10530-4","DOI":"10.1007\/s12015-023-10530-4"},{"issue":"3","key":"10620_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/biomedicines11030830","volume":"11","author":"A Heydemann","year":"2023","unstructured":"Heydemann, A., & Siemionow, M. (2023). A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines, 11(3), 830. https:\/\/doi.org\/10.3390\/biomedicines11030830","journal-title":"Biomedicines"},{"key":"10620_CR37","doi-asserted-by":"publisher","unstructured":"Mazzone, E. S., Messina, S., Vasco, G., Main, M., Eagle, M., D\u2019Amico, A., \u2026 Mercuri, E. (2009). Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders, 19(7), 458\u2013461. https:\/\/doi.org\/10.1016\/j.nmd.2009.06.368","DOI":"10.1016\/j.nmd.2009.06.368"},{"key":"10620_CR38","doi-asserted-by":"publisher","unstructured":"Mazzone, E., Martinelli, D., Berardinelli, A., Messina, S., D\u2019Amico, A., Vasco, G., \u2026 Mercuri, E. (2010). North Star ambulatory assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 20(11), 712\u2013716. https:\/\/doi.org\/10.1016\/j.nmd.2010.06.014","DOI":"10.1016\/j.nmd.2010.06.014"},{"key":"10620_CR39","doi-asserted-by":"publisher","unstructured":"Pane, M., Coratti, G., Brogna, C., Mazzone, E. S., Mayhew, A., Fanelli, L., \u2026 Mercuri, E. (2018). Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLOS ONE, 13(6), e0199223. https:\/\/doi.org\/10.1371\/journal.pone.0199223","DOI":"10.1371\/journal.pone.0199223"},{"key":"10620_CR40","doi-asserted-by":"publisher","unstructured":"Mayhew, A. G., Coratti, G., Mazzone, E. S., Klingels, K., James, M., Pane, M., \u2026 Selby, V. (2020). Performance of Upper Limb module for Duchenne muscular dystrophy. Developmental Medicine & Child Neurology, 62(5), 633\u2013639. https:\/\/doi.org\/10.1111\/dmcn.14361","DOI":"10.1111\/dmcn.14361"},{"issue":"5","key":"10620_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","volume":"72","author":"A \u0141oboda","year":"2020","unstructured":"\u0141oboda, A., & Dulak, J. (2020). Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: Past, present, and future. Pharmacological Reports: PR, 72(5), 1227\u20131263. https:\/\/doi.org\/10.1007\/s43440-020-00134-x","journal-title":"Pharmacological Reports: PR"},{"issue":"8","key":"10620_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/genes11080837","volume":"11","author":"C Sun","year":"2020","unstructured":"Sun, C., Shen, L., Zhang, Z., & Xie, X. (2020). Therapeutic strategies for Duchenne muscular dystrophy: An update. Genes, 11(8), 837. https:\/\/doi.org\/10.3390\/genes11080837","journal-title":"Genes"},{"issue":"1","key":"10620_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021). Duchenne muscular dystrophy. Nature Reviews. Disease Primers, 7(1), 13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3","journal-title":"Nature Reviews. Disease Primers"},{"issue":"3","key":"10620_CR44","doi-asserted-by":"publisher","first-page":"e0265879","DOI":"10.1371\/journal.pone.0265879","volume":"17","author":"N Ferizovic","year":"2022","unstructured":"Ferizovic, N., Summers, J., de Z\u00e1rate, I. B. O., Werner, C., Jiang, J., Landfeldt, E., & Buesch, K. (2022). Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis. PloS One, 17(3), e0265879. https:\/\/doi.org\/10.1371\/journal.pone.0265879","journal-title":"PloS One"},{"key":"10620_CR45","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez BattiAngulski","year":"2023","unstructured":"Bez BattiAngulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023). Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Frontiers in Physiology, 14, 1183101. https:\/\/doi.org\/10.3389\/fphys.2023.1183101","journal-title":"Frontiers in Physiology"},{"issue":"3","key":"10620_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-g","volume":"26","author":"G Nigro","year":"1990","unstructured":"Nigro, G., Comi, L. I., Politano, L., & Bain, R. J. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. International Journal of Cardiology, 26(3), 271\u2013277. https:\/\/doi.org\/10.1016\/0167-5273(90)90082-g","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10620_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00246-004-0689-2","volume":"26","author":"C Kirchmann","year":"2005","unstructured":"Kirchmann, C., Kececioglu, D., Korinthenberg, R., & Dittrich, S. (2005). Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatric Cardiology, 26(1), 66\u201372. https:\/\/doi.org\/10.1007\/s00246-004-0689-2","journal-title":"Pediatric Cardiology"},{"key":"10620_CR48","doi-asserted-by":"publisher","unstructured":"Connuck, D. M., Sleeper, L. A., Colan, S. D., Cox, G. F., Towbin, J. A., Lowe, A. M., \u2026 Lipshultz, S. E. (2008). Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the pediatric cardiomyopathy registry. American Heart Journal, 155(6), 998\u20131005. https:\/\/doi.org\/10.1016\/j.ahj.2008.01.018","DOI":"10.1016\/j.ahj.2008.01.018"},{"key":"10620_CR49","doi-asserted-by":"publisher","unstructured":"Tandon, A., Villa, C. R., Hor, K. N., Jefferies, J. L., Gao, Z., Towbin, J. A., \u2026 Taylor, M. D. (2015). Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 4(4), e001338. https:\/\/doi.org\/10.1161\/JAHA.114.001338","DOI":"10.1161\/JAHA.114.001338"},{"issue":"21","key":"10620_CR50","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","volume":"67","author":"F Kamdar","year":"2016","unstructured":"Kamdar, F., & Garry, D. J. (2016). Dystrophin-deficient cardiomyopathy. Journal of the American College of Cardiology, 67(21), 2533\u20132546. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.081","journal-title":"Journal of the American College of Cardiology"},{"key":"10620_CR51","doi-asserted-by":"publisher","unstructured":"Power, A., Poonja, S., Disler, D., Myers, K., Patton, D. J., Mah, J. K., \u2026 Greenway, S. C. (2017). Echocardiographic image quality deteriorates with age in children and young adults with Duchenne muscular dystrophy. Frontiers in Cardiovascular Medicine, 4, 82. https:\/\/doi.org\/10.3389\/fcvm.2017.00082","DOI":"10.3389\/fcvm.2017.00082"},{"issue":"12","key":"10620_CR52","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14779072.2020.1828065","volume":"18","author":"F de Souza","year":"2020","unstructured":"de Souza, F., BittarBraune, C., & Dos Santos Nucera, A. P. C. (2020). Duchenne muscular dystrophy: An overview to the cardiologist. Expert Review of Cardiovascular Therapy, 18(12), 867\u2013872. https:\/\/doi.org\/10.1080\/14779072.2020.1828065","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"1","key":"10620_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12947-020-00209-y","volume":"18","author":"G Song","year":"2020","unstructured":"Song, G., Zhang, J., Wang, X., Zhang, X., Sun, F., & Yu, X. (2020). Usefulness of speckle-tracking echocardiography for early detection in children with Duchenne muscular dystrophy: A meta-analysis and trial sequential analysis. Cardiovascular Ultrasound, 18(1), 26. https:\/\/doi.org\/10.1186\/s12947-020-00209-y","journal-title":"Cardiovascular Ultrasound"},{"issue":"4","key":"10620_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ppul.25175","volume":"56","author":"SG Wittekind","year":"2021","unstructured":"Wittekind, S. G., & Villa, C. R. (2021). Cardiac medication management in Duchenne muscular dystrophy. Pediatric Pulmonology, 56(4), 747\u2013752. https:\/\/doi.org\/10.1002\/ppul.25175","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10620_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ppul.21204","volume":"45","author":"J Gayraud","year":"2010","unstructured":"Gayraud, J., Ramonatxo, M., Rivier, F., Humberclaude, V., Petrof, B., & Matecki, S. (2010). Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients. Pediatric Pulmonology, 45(6), 552\u2013559. https:\/\/doi.org\/10.1002\/ppul.21204","journal-title":"Pediatric Pulmonology"},{"key":"10620_CR56","doi-asserted-by":"publisher","unstructured":"Abresch, R. T., McDonald, C. M., Henricson, E. K., Gustavo, N., Hu, F., Duong, T., \u2026 Mah, J. (2013). P.11.11 Pulmonary function characteristics of boys with Duchenne Muscular Dystrophy by age groups, ambulatory status and steroid use. Neuromuscular Disorders, 23(9), 801\u2013802. https:\/\/doi.org\/10.1016\/j.nmd.2013.06.572","DOI":"10.1016\/j.nmd.2013.06.572"},{"key":"10620_CR57","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2147\/TCRM.S55889","volume":"11","author":"A LoMauro","year":"2015","unstructured":"LoMauro, A., D\u2019Angelo, M. G., & Aliverti, A. (2015). Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: Current and emerging options. Therapeutics and Clinical Risk Management, 11, 1475\u20131488. https:\/\/doi.org\/10.2147\/TCRM.S55889","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"9","key":"10620_CR58","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/life11090947","volume":"11","author":"F Pennati","year":"2021","unstructured":"Pennati, F., LoMauro, A., D\u2019Angelo, M. G., & Aliverti, A. (2021). Non-invasive respiratory assessment in Duchenne muscular dystrophy: From clinical research to outcome measures. Life, 11(9), 947. https:\/\/doi.org\/10.3390\/life11090947","journal-title":"Life"},{"issue":"4","key":"10620_CR59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3233\/JND-150116","volume":"2","author":"A Hotta","year":"2015","unstructured":"Hotta, A. (2015). Genome editing gene therapy for Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 2(4), 343\u2013355. https:\/\/doi.org\/10.3233\/JND-150116","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"2","key":"10620_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1460-9592.2005.01801.x","volume":"16","author":"TA Yemen","year":"2006","unstructured":"Yemen, T. A., & McClain, C. (2006). Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Paediatric Anaesthesia, 16(2), 105\u2013108. https:\/\/doi.org\/10.1111\/j.1460-9592.2005.01801.x","journal-title":"Paediatric Anaesthesia"},{"issue":"2","key":"10620_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1460-9592.2007.02302.x","volume":"18","author":"J Hayes","year":"2008","unstructured":"Hayes, J., Veyckemans, F., & Bissonnette, B. (2008). Duchenne muscular dystrophy: An old anesthesia problem revisited. Paediatric Anaesthesia, 18(2), 100\u2013106. https:\/\/doi.org\/10.1111\/j.1460-9592.2007.02302.x","journal-title":"Paediatric Anaesthesia"},{"key":"10620_CR62","doi-asserted-by":"publisher","unstructured":"Birnkrant, D. J., Panitch, H. B., Benditt, J. O., Boitano, L. J., Carter, E. R., Cwik, V. A., \u2026 Sussman, M. D. (2007). American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest, 132(6), 1977\u20131986. https:\/\/doi.org\/10.1378\/chest.07-0458","DOI":"10.1378\/chest.07-0458"},{"issue":"10","key":"10620_CR63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/EJA.0b013e3283566789","volume":"29","author":"T Muenster","year":"2012","unstructured":"Muenster, T., Mueller, C., Forst, J., Huber, H., & Schmitt, H. J. (2012). Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: A review of 232 cases. European Journal of Anaesthesiology, 29(10), 489\u2013494. https:\/\/doi.org\/10.1097\/EJA.0b013e3283566789","journal-title":"European Journal of Anaesthesiology"},{"issue":"1","key":"10620_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12871-019-0887-3","volume":"19","author":"U Gurunathan","year":"2019","unstructured":"Gurunathan, U., Kunju, S. M., & Stanton, L. M. L. (2019). Use of sugammadex in patients with neuromuscular disorders: A systematic review of case reports. BMC Anesthesiology, 19(1), 213. https:\/\/doi.org\/10.1186\/s12871-019-0887-3","journal-title":"BMC Anesthesiology"},{"issue":"9","key":"10620_CR65","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/pan.12248","volume":"23","author":"LG Segura","year":"2013","unstructured":"Segura, L. G., Lorenz, J. D., Weingarten, T. N., Scavonetto, F., Bojani\u0107, K., Selcen, D., & Sprung, J. (2013). Anesthesia and Duchenne or Becker muscular dystrophy: Review of 117 anesthetic exposures. Paediatric Anaesthesia, 23(9), 855\u2013864. https:\/\/doi.org\/10.1111\/pan.12248","journal-title":"Paediatric Anaesthesia"},{"issue":"4","key":"10620_CR66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","volume":"122","author":"S Hemphill","year":"2019","unstructured":"Hemphill, S., McMenamin, L., Bellamy, M. C., & Hopkins, P. M. (2019). Propofol infusion syndrome: A structured literature review and analysis of published case reports. British Journal of Anaesthesia, 122(4), 448\u2013459. https:\/\/doi.org\/10.1016\/j.bja.2018.12.025","journal-title":"British Journal of Anaesthesia"},{"key":"10620_CR67","doi-asserted-by":"publisher","unstructured":"Horikoshi, Y., Kuratani, N., Tateno, K., Hoshijima, H., Nakamura, T., Mieda, T., \u2026 Nagasaka, H. (2021). Anesthetic management with remimazolam for a pediatric patient with Duchenne muscular dystrophy. Medicine, 100(49), e28209. https:\/\/doi.org\/10.1097\/MD.0000000000028209","DOI":"10.1097\/MD.0000000000028209"},{"key":"10620_CR68","doi-asserted-by":"publisher","unstructured":"van den Bersselaar, L. R., Heytens, L., Silva, H. C. A., Reimann, J., Tasca, G., D\u00edaz\u2010Cambronero, \u00d3., \u2026 Snoeck, M. M. J. (2022). European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders. European Journal of Neurology, 29(12), 3486\u20133507. https:\/\/doi.org\/10.1111\/ene.15526","DOI":"10.1111\/ene.15526"},{"issue":"7","key":"10620_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan, D. (2018). Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Human Gene Therapy, 29(7), 733\u2013736. https:\/\/doi.org\/10.1089\/hum.2018.012","journal-title":"Human Gene Therapy"},{"issue":"1","key":"10620_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm9010001","volume":"9","author":"Y Shimizu-Motohashi","year":"2019","unstructured":"Shimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019). Restoring dystrophin expression in Duchenne muscular dystrophy: Current status of therapeutic approaches. Journal of Personalized Medicine, 9(1), 1. https:\/\/doi.org\/10.3390\/jpm9010001","journal-title":"Journal of Personalized Medicine"},{"issue":"22","key":"10620_CR71","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim, A. S., & Avorn, J. (2016). Approving a problematic muscular dystrophy drug: Implications for FDA policy. JAMA, 316(22), 2357\u20132358. https:\/\/doi.org\/10.1001\/jama.2016.16437","journal-title":"JAMA"},{"key":"10620_CR72","doi-asserted-by":"publisher","unstructured":"Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., \u2026 Eteplirsen Study Group and Telethon Foundation DMD Italian Network. (2016). Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of Neurology, 79(2), 257\u2013271. https:\/\/doi.org\/10.1002\/ana.24555","DOI":"10.1002\/ana.24555"},{"issue":"1","key":"10620_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JND-170272","volume":"5","author":"TB Kinane","year":"2018","unstructured":"Kinane, T. B., Mayer, O. H., Duda, P. W., Lowes, L. P., Moody, S. L., & Mendell, J. R. (2018). Long-term pulmonary function in Duchenne muscular dystrophy: Comparison of Eteplirsen-treated patients to natural history. Journal of Neuromuscular Diseases, 5(1), 47\u201358. https:\/\/doi.org\/10.3233\/JND-170272","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10620_CR74","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng, J., Zhang, J., Shi, K., & Liu, Z. (2022). Drug development progress in Duchenne muscular dystrophy. Frontiers in Pharmacology, 13, 950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651","journal-title":"Frontiers in Pharmacology"},{"key":"10620_CR75","unstructured":"FDA Briefing Document BLA# 125781\/00 Drug Name: Delandistrogene Moxeparvovec Applicant: Sarepta Therapeutics, Inc. Cellular, Tissue and Gene Therapies Advisory Committee Meeting 05\/12\/2023 Office of Therapeutic Products (OTP) \/ CBER. (n.d.). Retrieved June 13, 2023, from https:\/\/www.fda.gov\/media\/168021\/download.\u00a0Accessed 12 Jun 2023."},{"issue":"6","key":"10620_CR76","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/mus.25678","volume":"56","author":"S Verma","year":"2017","unstructured":"Verma, S., Lin, J., Travers, C., McCracken, C., & Shah, D. (2017). Quantitative electromyography in ambulatory boys with Duchenne muscular dystrophy. Muscle & Nerve, 56(6), 1168\u20131171. https:\/\/doi.org\/10.1002\/mus.25678","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10620_CR77","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pjnns.2015.05.005","volume":"49","author":"E Szmidt-Sa\u0142kowska","year":"2015","unstructured":"Szmidt-Sa\u0142kowska, E., Gawe\u0142, M., & Lipowska, M. (2015). Motor unit reorganization in progressive muscular dystrophies and congenital myopathies. Neurologia i Neurochirurgia Polska, 49(4), 223\u2013228. https:\/\/doi.org\/10.1016\/j.pjnns.2015.05.005","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"4","key":"10620_CR78","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.22341","volume":"45","author":"KL Derry","year":"2012","unstructured":"Derry, K. L., Venance, S. L., & Doherty, T. J. (2012). Decomposition-based quantitative electromyography in the evaluation of muscular dystrophy severity. Muscle & Nerve, 45(4), 507\u2013513. https:\/\/doi.org\/10.1002\/mus.22341","journal-title":"Muscle & Nerve"},{"key":"10620_CR79","doi-asserted-by":"publisher","unstructured":"Klimczak, A., Zimna, A., Malcher, A., Kozlowska, U., Futoma, K., Czarnota, J., \u2026 Kurpisz, M. (2020). Co-transplantation of bone marrow-MSCs and myogenic stem\/progenitor cells from adult donors improves muscle function of patients with Duchenne muscular dystrophy. Cells, 9(5), 1119. https:\/\/doi.org\/10.3390\/cells9051119","DOI":"10.3390\/cells9051119"},{"key":"10620_CR80","doi-asserted-by":"publisher","unstructured":"Ropars, J., Lempereur, M., Vuillerot, C., Tiffreau, V., Peudenier, S., Cuisset, J.-M., \u2026 Brochard, S. (2016). Muscle activation during gait in children with Duchenne muscular dystrophy. PLOS ONE, 11(9), e0161938. https:\/\/doi.org\/10.1371\/journal.pone.0161938","DOI":"10.1371\/journal.pone.0161938"},{"issue":"11","key":"10620_CR81","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1016\/j.clinph.2005.01.017","volume":"116","author":"K Rowi\u0144ska-Marci\u0144ska","year":"2005","unstructured":"Rowi\u0144ska-Marci\u0144ska, K., Szmidt-Sa\u0142kowska, E., Fidzia\u0144ska, A., Zalewska, E., Dorobek, M., Karwa\u0144ska, A., & Hausmanowa-Petrusewicz, I. (2005). Atypical motor unit potentials in Emery-Dreifuss muscular dystrophy (EDMD). Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology, 116(11), 2520\u20132527. https:\/\/doi.org\/10.1016\/j.clinph.2005.01.017","journal-title":"Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology"},{"issue":"3","key":"10620_CR82","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jelekin.2012.11.002","volume":"23","author":"E Zalewska","year":"2013","unstructured":"Zalewska, E., Szmidt-Salkowska, E., Rowinska-Marcinska, K., Kaminska, A., & Hausmanowa-Petrusewicz, I. (2013). Motor unit potentials with satellites in dystrophinopathies. Journal of Electromyography and Kinesiology, 23(3), 580\u2013586. https:\/\/doi.org\/10.1016\/j.jelekin.2012.11.002","journal-title":"Journal of Electromyography and Kinesiology"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-023-10620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-023-10620-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-023-10620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:16:44Z","timestamp":1700482604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-023-10620-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10620"],"URL":"https:\/\/doi.org\/10.1007\/s12015-023-10620-3","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"28 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval no. 46\/2019). All procedures performed in the study involving human participants were conducted in accordance with the Good Clinical Practice (GCP) guidelines and the ethical standards of\u00a01964\u00a0Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Freely-given, informed consent to participate in the study was obtained from all participants (or\u00a0their parent or legal guardian in the case of children under 16). The tissues were obtained in\u00a0MedPolonia Hospital (Poznan, Poland). No\u00a0tissues were obtained from prisoners.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"MS is CMO and shareholder of Dystrogen Therapeutics Corp. the company that holds a license for\u00a0DT-DEC01 therapy. MS is the inventor on the patent application filed by University of Illinois at\u00a0Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO\/2016\/201182). The\u00a0author declares a potential conflict of interest. KS is CEO and shareholder of Dystrogen Therapeutics Corp. The author declares a potential conflict of interest. GB, AN, JW and JC received fees for work related to this study. AZ, MHS and KB are Dystrogen Therapeutics Corp. employees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}